Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1336 to 1350 of 2187 results for guidelines

  1. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    or planning a return to work are treated consistently.The focus of this guideline is on managing sickness absence among all employees,...

    Research recommendation
    Published
    10 February 2020

  2. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  3. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

    HealthTech guidance
    Published
    7 August 2013
    View recommendations

    Sections for HTG315

  4. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  5. Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed prostate-specific antigen thresholds for people with symptoms of prostate cancer, including those at high risk of developing prostate cancer (such as those with an African family background or a family history of prostate cancer)?

    population that had already been referred to secondary care. The 2019 guideline recommended referral if PSA levels were above the...

    Research recommendation
    Published
    7 January 2022

  6. Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had radiotherapy less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  7. What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single, double, or boosted doses of the approved vaccinations in the UK? Does this vary across different population groups (for example in black, Asian and minority ethnic group communities)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  8. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

    Medtech innovation briefing
    Published
    30 January 2018

  9. Digitally enabled therapies for adults with depression: early value assessment (HTG675)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.

    HealthTech guidance
    Last updated
    14 January 2025
    View recommendations

    Sections for HTG675

  10. Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021

  11. Develop and validate new and existing screening tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for post‑COVID‑19 syndrome, which are the most accurate at identifying post‑COVID‑19 syndrome in a UK population and what is their effectiveness in guiding management?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    15 November 2021

  12. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

    HealthTech guidance
    Published
    7 October 2015

    Sections for HTG386

  13. What effects does isolation have on the quality of life of people being treated for TB?

    to significantly affect a person's quality of life. Despite this, the guideline committee identified no reliable data on the impact of...

    Research recommendation
    Published
    8 November 2019

  14. Prescribing beyond monotherapy:- What is the clinical and cost effectiveness of various ADHD prescribing strategies when monotherapy has failed?

    Any explanatory notes(if applicable) Why is this important:- This guideline makes recommendations for the medication choices for people...

    Research recommendation
    Published
    14 November 2018

  15. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682